Embleema's software platform brings precision medicine sooner to patients by collecting and generating regulatory-grade evidence. Our platform is used by the FDA for its regulatory evaluation of health products involving genomic datasets and is the basis for future CDISC standards for cell and gene therapies. When life sciences use HIVE, they align their bioinformatics submission with the FDA and accelerate the regulatory decision. The FDA also uses our platform to produce regulatory grade genomic sequences for SARS-CoV-2 and other microbial pathogens (project ARGOS). In addition to the FDA, our platform is used by leading pharmaceutical companies, biotechs, patient advocacy groups and clinical research centers.